Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Dr. Mark Awad is an Assistant Professor of Medicine at Harvard Medical School and Clinical Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute. He received his undergraduate degree from Harvard University and his MD and PhD degrees from the Johns Hopkins School of Medicine. He completed his residency and chief residency at the Massachusetts General Hospital, and his medical oncology fellowship at the Dana-Farber Cancer Institute before joining the Dana-Farber faculty in 2014. His translational research focus is on identifying biomarkers of response and resistance to targeted therapies and immunotherapies in lung cancer. He is the principal investigator of several clinical trials for patients with thoracic malignancies and collaborates closely with laboratory-based investigators. His research has been published in journals such as the New England Journal of Medicine, the Journal of Clinical Oncology, Cancer Immunology Research, and the Journal of Thoracic Oncology. He is a recipient of the 2015 Young Investigator Award from the American Society of Clinical Oncology (ASCO), the 2015 Young Investigator Award from the International Association for the Society of Lung Cancer (IASLC), the 2017 Career Development Award from Conquer Cancer Foundation of ASCO, and the 2018 ALK Positive/LUNGevity Transformational Research Award.
Immunotherapies and Vaccine Development
Dr. Awad's main area of research is on cancer immunotherapy and vaccine development. He has been working with a number of laboratories to study the genetics and immune microenvironemnt of lung tumors in order to develop better immune therapies for cancer patients. In addition, he conducts research on cancers whose growth is driven by mutations in genes such as RET, ROS1, and ALK, and he has been working to understand how these cancers acquire resistance to targeted therapies.
Dana-Farber Cancer Institute450 Brookline AvenueBoston, MA 02215Get Directions